Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
Fig 3
Probability of survival without thromboembolic events or all-cause death for patients who discontinued treatment with NOAC.
Time 0 is the time of the interruption/cessation. The 95% confidence intervals are marked with interrupted lines. All non-fatal thromboembolic events occurred within 37 days after interruption/cessation.